Axinn advised Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, on the completed sale of its microbiology business to Astorg, a leading pan-European private equity firm, for approximately $1.075 billion. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing.
The Axinn team included partners James Hunsberger and Mark Alexander and associates Megan Walden, Taylor Aiello, and Leandra Ipiña.
More details can be found here.